The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.
US approval of Lexicon and Sanofi’s SGLT inhibitor in type 1 diabetes hangs in the balance after an adcom tie.